25 XP   0   0   10

Helix BioPharma Corp
Buy, Hold or Sell?

Let's analyse Helix BioPharma Corp together

PenkeI guess you are interested in Helix BioPharma Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Helix BioPharma Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Helix BioPharma Corp

I send you an email if I find something interesting about Helix BioPharma Corp.

Quick analysis of Helix BioPharma Corp (30 sec.)










What can you expect buying and holding a share of Helix BioPharma Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$-0.02
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-10.6%

For what price can you sell your share?

Current Price per Share
$0.14
Expected price per share
$0.14 - $0.14
How sure are you?
50%

1. Valuation of Helix BioPharma Corp (5 min.)




Live pricePrice per Share (EOD)

$0.14

Intrinsic Value Per Share

$-0.16 - $0.06

Total Value Per Share

$-0.16 - $0.06

2. Growth of Helix BioPharma Corp (5 min.)




Is Helix BioPharma Corp growing?

Current yearPrevious yearGrowGrow %
How rich?-$618.8k$233.8k-$852.7k-137.8%

How much money is Helix BioPharma Corp making?

Current yearPrevious yearGrowGrow %
Making money-$4.6m-$4.8m$200.1k4.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Helix BioPharma Corp (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#863 / 998

Most Revenue
#941 / 998

Most Profit
#431 / 998

Most Efficient
#345 / 998

What can you expect buying and holding a share of Helix BioPharma Corp? (5 min.)

Welcome investor! Helix BioPharma Corp's management wants to use your money to grow the business. In return you get a share of Helix BioPharma Corp.

What can you expect buying and holding a share of Helix BioPharma Corp?

First you should know what it really means to hold a share of Helix BioPharma Corp. And how you can make/lose money.

Speculation

The Price per Share of Helix BioPharma Corp is $0.14. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Helix BioPharma Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Helix BioPharma Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Helix BioPharma Corp.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.02-14.4%-0.02-14.4%-0.02-15.0%-0.02-17.1%-0.03-18.8%
Usd Book Value Change Per Share0.00-2.7%0.00-2.7%0.013.9%0.000.3%0.00-1.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-2.7%0.00-2.7%0.013.9%0.000.3%0.00-1.3%
Usd Price Per Share0.14-0.14-0.15-0.37-0.40-
Price to Earnings Ratio-6.97--6.97--7.15--15.04--15.72-
Price-to-Total Gains Ratio-37.67--37.67-27.42--24.77-1.78-
Price to Book Ratio-51.91--51.91-147.15--13.68--11.60-
Price-to-Total Gains Ratio-37.67--37.67-27.42--24.77-1.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.14
Number of shares7142
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (7142 shares)-26.543.12
Gains per Year (7142 shares)-106.1712.47
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-106-1160122
20-212-22202514
30-319-32803726
40-425-43405038
50-531-54006250
60-637-64607562
70-743-75208774
80-849-858010086
90-956-964011298
100-1062-10700125110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.017.07.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%12.012.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.024.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%12.012.00.050.0%

Fundamentals of Helix BioPharma Corp

About Helix BioPharma Corp

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Fundamental data was last updated by Penke on 2024-05-15 02:47:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Helix BioPharma Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Helix BioPharma Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--211.9%+211.9%
YOY--263.3%+263.3%
5Y--414.0%+414.0%
10Y--552.3%+552.3%
1.1.2. Return on Assets

Shows how efficient Helix BioPharma Corp is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • -611.3% Return on Assets means that Helix BioPharma Corp generated $-6.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Helix BioPharma Corp:

  • The MRQ is -611.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -611.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-611.3%TTM-611.3%0.0%
TTM-611.3%YOY-176.0%-435.3%
TTM-611.3%5Y-393.7%-217.5%
5Y-393.7%10Y-362.0%-31.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-611.3%-11.9%-599.4%
TTM-611.3%-11.5%-599.8%
YOY-176.0%-10.9%-165.1%
5Y-393.7%-13.1%-380.6%
10Y-362.0%-14.4%-347.6%
1.1.3. Return on Equity

Shows how efficient Helix BioPharma Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • 0.0% Return on Equity means Helix BioPharma Corp generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,057.4%+2,057.4%
TTM-5Y-486.5%+486.5%
5Y-486.5%10Y-299.3%-187.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.3%+15.3%
TTM--14.6%+14.6%
YOY-2,057.4%-13.6%-2,043.8%
5Y-486.5%-17.7%-468.8%
10Y-299.3%-19.2%-280.1%

1.2. Operating Efficiency of Helix BioPharma Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Helix BioPharma Corp is operating .

  • Measures how much profit Helix BioPharma Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--336.0%+336.0%
TTM--224.0%+224.0%
YOY--280.1%+280.1%
5Y--412.2%+412.2%
10Y--521.7%+521.7%
1.2.2. Operating Ratio

Measures how efficient Helix BioPharma Corp is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.005-3.005
TTM-3.247-3.247
YOY-3.619-3.619
5Y-5.262-5.262
10Y-6.874-6.874

1.3. Liquidity of Helix BioPharma Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Helix BioPharma Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.53 means the company has $0.53 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.531. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.531. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.531TTM0.5310.000
TTM0.531YOY1.083-0.552
TTM0.5315Y1.047-0.516
5Y1.04710Y2.435-1.388
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5313.805-3.274
TTM0.5314.158-3.627
YOY1.0835.252-4.169
5Y1.0476.087-5.040
10Y2.4356.434-3.999
1.3.2. Quick Ratio

Measures if Helix BioPharma Corp is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • A Quick Ratio of 0.46 means the company can pay off $0.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.464. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.464. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.464TTM0.4640.000
TTM0.464YOY1.035-0.571
TTM0.4645Y0.984-0.520
5Y0.98410Y2.359-1.375
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4643.202-2.738
TTM0.4643.816-3.352
YOY1.0355.183-4.148
5Y0.9845.929-4.945
10Y2.3596.351-3.992

1.4. Solvency of Helix BioPharma Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Helix BioPharma Corp assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Helix BioPharma Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.82 means that Helix BioPharma Corp assets are financed with 182.0% credit (debt) and the remaining percentage (100% - 182.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Helix BioPharma Corp:

  • The MRQ is 1.820. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.820. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.820TTM1.8200.000
TTM1.820YOY0.914+0.906
TTM1.8205Y1.792+0.028
5Y1.79210Y1.285+0.507
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8200.344+1.476
TTM1.8200.342+1.478
YOY0.9140.279+0.635
5Y1.7920.366+1.426
10Y1.2850.380+0.905
1.4.2. Debt to Equity Ratio

Measures if Helix BioPharma Corp is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY10.693-10.693
TTM-5Y2.299-2.299
5Y2.29910Y1.220+1.079
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM-0.415-0.415
YOY10.6930.353+10.340
5Y2.2990.446+1.853
10Y1.2200.470+0.750

2. Market Valuation of Helix BioPharma Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Helix BioPharma Corp generates.

  • Above 15 is considered overpriced but always compare Helix BioPharma Corp to the Biotechnology industry mean.
  • A PE ratio of -6.97 means the investor is paying $-6.97 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Helix BioPharma Corp:

  • The EOD is -6.965. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.965. Based on the earnings, the company is expensive. -2
  • The TTM is -6.965. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.965MRQ-6.9650.000
MRQ-6.965TTM-6.9650.000
TTM-6.965YOY-7.152+0.187
TTM-6.9655Y-15.041+8.076
5Y-15.04110Y-15.718+0.677
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.965-2.276-4.689
MRQ-6.965-2.535-4.430
TTM-6.965-2.723-4.242
YOY-7.152-3.942-3.210
5Y-15.041-6.316-8.725
10Y-15.718-6.544-9.174
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Helix BioPharma Corp:

  • The EOD is -7.912. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.912. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.912. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.912MRQ-7.9120.000
MRQ-7.912TTM-7.9120.000
TTM-7.912YOY-7.211-0.701
TTM-7.9125Y-15.378+7.466
5Y-15.37810Y-16.388+1.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.912-3.153-4.759
MRQ-7.912-3.270-4.642
TTM-7.912-3.527-4.385
YOY-7.211-5.220-1.991
5Y-15.378-8.080-7.298
10Y-16.388-8.650-7.738
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Helix BioPharma Corp is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -51.91 means the investor is paying $-51.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Helix BioPharma Corp:

  • The EOD is -51.908. Based on the equity, the company is expensive. -2
  • The MRQ is -51.908. Based on the equity, the company is expensive. -2
  • The TTM is -51.908. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-51.908MRQ-51.9080.000
MRQ-51.908TTM-51.9080.000
TTM-51.908YOY147.146-199.054
TTM-51.9085Y-13.678-38.230
5Y-13.67810Y-11.604-2.074
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-51.9082.066-53.974
MRQ-51.9082.029-53.937
TTM-51.9082.065-53.973
YOY147.1462.688+144.458
5Y-13.6783.688-17.366
10Y-11.6044.088-15.692
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Helix BioPharma Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.004-0.0040%0.005-168%0.000-951%-0.002-50%
Book Value Per Share---0.003-0.0030%0.001-365%-0.001-47%0.004-165%
Current Ratio--0.5310.5310%1.083-51%1.047-49%2.435-78%
Debt To Asset Ratio--1.8201.8200%0.914+99%1.792+2%1.285+42%
Debt To Equity Ratio----0%10.693-100%2.299-100%1.220-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.020-0.0200%-0.021+4%-0.024+19%-0.026+31%
Free Cash Flow Per Share---0.018-0.0180%-0.021+18%-0.024+36%-0.026+45%
Free Cash Flow To Equity Per Share---0.008-0.0080%-0.001-88%-0.002-73%-0.002-69%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.059--------
Intrinsic Value_10Y_min---0.161--------
Intrinsic Value_1Y_max---0.017--------
Intrinsic Value_1Y_min---0.023--------
Intrinsic Value_3Y_max---0.033--------
Intrinsic Value_3Y_min---0.065--------
Intrinsic Value_5Y_max---0.028--------
Intrinsic Value_5Y_min---0.099--------
Market Cap32121738.8800%32121738.88032121738.8800%34416148.800-7%85810931.008-63%91776396.800-65%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-51.9080%-51.908-51.9080%147.146-135%-13.678-74%-11.604-78%
Pe Ratio-6.9650%-6.965-6.9650%-7.152+3%-15.041+116%-15.718+126%
Price Per Share0.1400%0.1400.1400%0.150-7%0.374-63%0.400-65%
Price To Free Cash Flow Ratio-7.9120%-7.912-7.9120%-7.211-9%-15.378+94%-16.388+107%
Price To Total Gains Ratio-37.6700%-37.670-37.6700%27.418-237%-24.769-34%1.780-2216%
Quick Ratio--0.4640.4640%1.035-55%0.984-53%2.359-80%
Return On Assets---6.113-6.1130%-1.760-71%-3.937-36%-3.620-41%
Return On Equity----0%-20.5740%-4.8650%-2.9930%
Total Gains Per Share---0.004-0.0040%0.005-168%0.000-951%-0.002-50%
Usd Book Value---618820.800-618820.8000%233890.800-365%-325247.520-47%956092.800-165%
Usd Book Value Change Per Share---0.004-0.0040%0.005-168%0.000-951%-0.002-50%
Usd Book Value Per Share---0.003-0.0030%0.001-365%-0.001-47%0.004-165%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.020-0.0200%-0.021+4%-0.024+19%-0.026+31%
Usd Free Cash Flow---4059728.400-4059728.4000%-4772398.800+18%-5532287.280+36%-5870805.720+45%
Usd Free Cash Flow Per Share---0.018-0.0180%-0.021+18%-0.024+36%-0.026+45%
Usd Free Cash Flow To Equity Per Share---0.008-0.0080%-0.001-88%-0.002-73%-0.002-69%
Usd Market Cap32121738.8800%32121738.88032121738.8800%34416148.800-7%85810931.008-63%91776396.800-65%
Usd Price Per Share0.1400%0.1400.1400%0.150-7%0.374-63%0.400-65%
Usd Profit---4611828.000-4611828.0000%-4811991.600+4%-5484629.280+19%-6097511.160+32%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.004-0.0040%0.005-168%0.000-951%-0.002-50%
 EOD+0 -0MRQTTM+0 -0YOY+10 -185Y+9 -1910Y+9 -19

3.2. Fundamental Score

Let's check the fundamental score of Helix BioPharma Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.965
Price to Book Ratio (EOD)Between0-1-51.908
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.464
Current Ratio (MRQ)Greater than10.531
Debt to Asset Ratio (MRQ)Less than11.820
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-6.113
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Helix BioPharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.841
Ma 20Greater thanMa 500.140
Ma 50Greater thanMa 1000.141
Ma 100Greater thanMa 2000.141
OpenGreater thanClose0.140
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-07-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets1,029
Total Liabilities1,873
Total Stockholder Equity-844
 As reported
Total Liabilities 1,873
Total Stockholder Equity+ -844
Total Assets = 1,029

Assets

Total Assets1,029
Total Current Assets996
Long-term Assets33
Total Current Assets
Cash And Cash Equivalents 808
Net Receivables 62
Other Current Assets 126
Total Current Assets  (as reported)996
Total Current Assets  (calculated)996
+/-0
Long-term Assets
Property Plant Equipment 33
Long-term Assets  (as reported)33
Long-term Assets  (calculated)33
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities1,874
Long-term Liabilities-1
Total Stockholder Equity-844
Total Current Liabilities
Accounts payable 493
Other Current Liabilities 1,381
Total Current Liabilities  (as reported)1,874
Total Current Liabilities  (calculated)1,874
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)-1
Long-term Liabilities  (calculated)0
+/- 1
Total Stockholder Equity
Common Stock152,068
Retained Earnings -201,407
Accumulated Other Comprehensive Income 4,357
Other Stockholders Equity 44,138
Total Stockholder Equity (as reported)-844
Total Stockholder Equity (calculated)-844
+/-0
Other
Capital Stock152,068
Cash and Short Term Investments 808
Common Stock Shares Outstanding 193,229
Liabilities and Stockholders Equity 1,029
Net Debt -808
Net Invested Capital -844
Net Working Capital -878
Property Plant and Equipment Gross 1,824



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-07-312022-07-312021-07-312020-07-312019-07-312018-07-312017-07-312016-07-312015-07-312014-07-312013-07-312012-07-312011-07-312010-07-312009-07-312008-07-312007-07-312006-07-312005-07-312004-07-312003-07-312002-07-312001-07-312000-07-31
> Total Assets 
9,875
11,930
9,047
11,491
9,388
9,448
13,668
14,273
21,666
19,319
18,114
24,371
7,616
5,868
7,853
7,796
4,468
2,187
1,147
940
4,906
4,065
3,730
1,029
1,0293,7304,0654,9069401,1472,1874,4687,7967,8535,8687,61624,37118,11419,31921,66614,27313,6689,4489,38811,4919,04711,9309,875
   > Total Current Assets 
0
0
0
0
0
0
0
13,007
20,310
17,454
15,668
21,680
6,123
5,191
7,405
7,467
4,233
1,700
773
687
4,660
4,018
3,695
996
9963,6954,0184,6606877731,7004,2337,4677,4055,1916,12321,68015,66817,45420,31013,0070000000
       Cash And Cash Equivalents 
2,039
2,518
1,928
1,342
2,699
3,408
3,881
11,379
19,057
14,494
13,125
19,044
4,862
4,493
6,980
6,792
3,654
897
366
206
4,235
3,565
3,252
808
8083,2523,5654,2352063668973,6546,7926,9804,4934,86219,04413,12514,49419,05711,3793,8813,4082,6991,3421,9282,5182,039
       Short-term Investments 
6,148
6,932
5,409
4,931
2,241
2,038
5,867
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000005,8672,0382,2414,9315,4096,9326,148
       Net Receivables 
0
0
0
0
0
0
0
902
349
1,053
1,365
1,906
733
559
343
491
489
630
315
290
180
353
280
62
622803531802903156304894913435597331,9061,3651,0533499020000000
       Other Current Assets 
118
97
134
170
136
234
141
187
446
1,049
398
202
107
1
0
1
90
173
92
191
245
100
-1
126
126-110024519192173901011072023981,04944618714123413617013497118
   > Long-term Assets 
0
0
0
0
0
0
0
1,266
1,356
1,865
2,446
2,691
1,493
677
448
329
235
487
374
253
246
47
35
33
3335472462533744872353294486771,4932,6912,4461,8651,3561,2660000000
       Property Plant Equipment 
460
867
695
885
1,009
1,172
1,204
1,139
1,151
1,809
1,987
2,031
1,049
677
448
329
235
487
374
253
246
47
35
33
3335472462533744872353294486771,0492,0311,9871,8091,1511,1391,2041,1721,009885695867460
       Long Term Investments 
0
0
0
0
0
0
0
0
0
52
436
723
0
0
0
0
0
0
0
0
0
0
0
0
00000000000072343652000000000
       Intangible Assets 
151
134
114
3,649
2,914
1,824
1,429
126
110
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001101261,4291,8242,9143,649114134151
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
459
660
444
0
0
0
0
0
0
0
0
0
1
0
010000000004446604590000000000
> Total Liabilities 
926
718
704
520
969
947
1,403
1,539
1,144
2,256
2,353
2,258
1,392
948
1,042
969
1,304
2,204
2,674
4,221
1,925
5,458
3,411
1,873
1,8733,4115,4581,9254,2212,6742,2041,3049691,0429481,3922,2582,3532,2561,1441,5391,403947969520704718926
   > Total Current Liabilities 
763
616
632
469
941
932
1,403
1,539
1,144
2,158
2,281
2,210
1,369
948
1,042
969
1,304
2,204
2,674
4,221
1,925
3,874
3,411
1,874
1,8743,4113,8741,9254,2212,6742,2041,3049691,0429481,3692,2102,2812,1581,1441,5391,403932941469632616763
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
2,028
2,468
0
02,4682,02815900000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,028
2,468
0
02,4682,028000000000000000000000
       Accounts payable 
739
591
609
443
922
875
1,389
565
598
1,299
1,435
1,085
650
304
566
262
715
1,438
1,992
3,040
1,416
1,466
599
493
4935991,4661,4163,0401,9921,4387152625663046501,0851,4351,2995985651,389875922443609591739
       Other Current Liabilities 
0
0
0
0
0
41
0
974
546
859
846
1,125
719
644
476
707
589
722
644
1,057
49
380
-1
1,381
1,381-1380491,0576447225897074766447191,12584685954697404100000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
98
72
48
23
0
0
0
0
0
0
0
0
1,584
0
-1
-101,5840000000023487298000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
91
70
50
23
0
0
0
0
0
0
0
0
0
0
0
0000000000023507091000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
91
68
52
0
0
0
0
0
0
0
0
0
0
0
0
000000000000526891000000000
> Total Stockholder Equity
8,814
10,801
8,113
10,971
8,419
8,501
12,265
12,734
20,522
17,063
15,761
22,113
6,224
4,920
6,811
6,827
3,164
-17
-1,527
-3,281
2,394
-1,393
319
-844
-844319-1,3932,394-3,281-1,527-173,1646,8276,8114,9206,22422,11315,76117,06320,52212,73412,2658,5018,41910,9718,11310,8018,814
   Common Stock
15,829
20,676
20,016
26,372
28,910
35,952
45,895
53,734
70,312
75,673
88,661
106,878
102,077
101,407
107,079
112,288
116,146
120,681
125,565
129,532
137,257
139,660
147,511
152,068
152,068147,511139,660137,257129,532125,565120,681116,146112,288107,079101,407102,077106,87888,66175,67370,31253,73445,89535,95228,91026,37220,01620,67615,829
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
94
55
0
0
0
13
17
12
10,549
11,814
14,045
15,403
20,113
19,634
10,335
4,357
4,35710,33519,63420,11315,40314,04511,81410,549121713000559400000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
64,462
79,120
89,802
101,554
120,724
122,923
21,744
26,641
30,183
21,790
22,868
22,868
23,315
25,540
27,867
37,590
44,138
44,13837,59027,86725,54023,31522,86822,86821,79030,18326,64121,744122,923120,724101,55489,80279,12064,4620000000



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.